This drug works by combining the antibody trastuzumab with a drug called emtansine. Trastuzumab works by binding to HER2 proteins that are found on the cells of HER2-positive breast cancer.

("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 biparatopic antibody-drug ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatment technologies have opened new avenues for ...

Targeting these processes early is likely to offer unexpected therapeutic ... Trastuzumab Emtansine Improves Long-Term Survival in HER2 Breast Cancer Jan. 15, 2025 — In patients with high-risk ...

Several of these approved treatments have rapidly transitioned into blockbuster successes for their owners, such as Roche’s Kadcyla (trastuzumab emtansine), and Daiichi Sankyo and AstraZeneca ...

In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with ...

The deal with RemeGen gives Seagen a closer rival to AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) and Roche's Kadcyla (trastuzumab emtansine) – both HER2-targeting ADCs – but may ...

It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla and a highly effective drug for treatingboth early and ...

such as trastuzumab emtansine CDK4/6 inhibitors are a more recent treatment option to prevent cancer cell growth and include the drugs palbociclib, ribociclib, and abemaciclib. People may have ...

Begin hereto get started and access this resource. TDM-1: “First Therapy to Show Improved OS After Postsurgical Therapy” in HER+ BC Ado-trastuzumab emtansine (T-DM1; Kadcyla) continues to show ...